This provides Zelda with an opportunity to collaborate with a panel of leading international medicinal cannabis experts.
The ICCI is an international centre of excellence for the advancement of cannabis and cannabinoid treatments.
The ICCI provides access to a global network of specialist services including expert advice on clinical study design and execution, requirements for regulatory approval, a full range of contract research services and direct liaison with study investigators.
Zelda’s managing director Dr Richard Hopkins said: “We’re honoured to be working with the ICCI and Dr Ethan Russo, who are recognised globally as leading authorities on medicinal cannabis. Their insights will help inform and accelerate our clinical trial programs.
“Dr Russo and the ICCI will complement our existing medical advisory team and maintains Zelda’s strategy of engaging the world’s best medicinal cannabis researchers and clinicians.”
Dr Ethan Russo was recently appointed the Director of Research and Development at the ICCI.
Dr Russo said: “I’m delighted to be collaborating with Zelda who is at the forefront of efforts to develop plant-derived cannabis medicines that have the potential to improve quality of life for patients.”
Progressing clinical and pre-clinical activities in 2019
Zelda remains on-track to report on the outcome from its clinical trials for insomnia, autism and opioid reduction by mid-2019.
The company is also continuing to assess opportunities to expand its clinical programs where they align with its strategic objectives.
Finally, Zelda is progressing discussions with third parties aiming at securing agreements to distribute clinically-validated Zelda products globally.